Opustan (Mefenamic Acid)

Mefenamic Acid, the active ingredient in Opustan, is a Nonsteroidal anti-inflammatory drug (NSAID) presented as a tablet for oral use. It relieves mild to moderate pain, dysmenorrhea, and inflammatory musculoskeletal conditions in adults.

GNH USA supplies Opustan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Opustan, a NSAID, acts on inflammatory pathways to provide analgesic and antipyretic effects.

- Mild to moderate pain: reduces pain intensity in conditions such as headache, dental pain, and postoperative discomfort. - Dysmenorrhea: alleviates menstrual cramps by decreasing uterine prostaglandin production. - Inflammatory musculoskeletal conditions: improves mobility and reduces swelling in arthritis and soft‑tissue injuries.

Adverse reactions may occur with Opustan use.

Common Side Effects: - Gastrointestinal discomfort: nausea, dyspepsia, or abdominal pain. - Headache: mild to moderate intensity. - Dizziness or vertigo: transient episodes.

Serious or Rare Side Effects: - Gastrointestinal ulceration or bleeding: may present with melena or hematemesis. - Renal impairment: reduced kidney function or acute renal failure. - Severe hypersensitivity: rash, angioedema, or anaphylactic reactions.

Opustan should be used with caution in certain situations.

- Cardiovascular risk: avoid in patients with established coronary artery disease. - Renal function: monitor kidney parameters in patients with pre‑existing renal impairment. - Hepatic disease: use carefully in individuals with liver dysfunction. - Concomitant anticoagulants: increase bleeding risk; monitor coagulation status. - Pregnancy and lactation: safety not established; discuss risks with a healthcare professional. - Store below 25°C: keep in the original pack, protect from moisture.

Opustan can interact with several medications.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): heightened bleeding risk. - Other NSAIDs or aspirin: increased gastrointestinal toxicity. - Lithium: elevated serum lithium levels.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: possible reduction in renal function. - Diuretics: risk of reduced renal perfusion. - Methotrexate: potential for increased toxicity.